Literature DB >> 25394790

Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.

Marc R Mansour1, Brian J Abraham2, Lars Anders2, Alla Berezovskaya3, Alejandro Gutierrez4, Adam D Durbin3, Julia Etchin3, Lee Lawton2, Stephen E Sallan4, Lewis B Silverman4, Mignon L Loh5, Stephen P Hunger6, Takaomi Sanda7, Richard A Young8, A Thomas Look9.   

Abstract

In certain human cancers, the expression of critical oncogenes is driven from large regulatory elements, called super-enhancers, that recruit much of the cell's transcriptional apparatus and are defined by extensive acetylation of histone H3 lysine 27 (H3K27ac). In a subset of T-cell acute lymphoblastic leukemia (T-ALL) cases, we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site, which creates a super-enhancer upstream of the TAL1 oncogene. MYB binds to this new site and recruits its H3K27 acetylase-binding partner CBP, as well as core components of a major leukemogenic transcriptional complex that contains RUNX1, GATA-3, and TAL1 itself. Additionally, most endogenous super-enhancers found in T-ALL cells are occupied by MYB and CBP, which suggests a general role for MYB in super-enhancer initiation. Thus, this study identifies a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25394790      PMCID: PMC4720521          DOI: 10.1126/science.1259037

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  2 in total

1.  Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes.

Authors:  T M Breit; E J Mol; I L Wolvers-Tettero; W D Ludwig; E R van Wering; J J van Dongen
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

2.  UniPROBE: an online database of protein binding microarray data on protein-DNA interactions.

Authors:  Daniel E Newburger; Martha L Bulyk
Journal:  Nucleic Acids Res       Date:  2008-10-08       Impact factor: 16.971

  2 in total
  342 in total

1.  Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor.

Authors:  Shiori Saito; Jiro Kikuchi; Daisuke Koyama; Shin Sato; Hiroo Koyama; Naoki Osada; Yoshiaki Kuroda; Koshi Akahane; Takeshi Inukai; Takashi Umehara; Yusuke Furukawa
Journal:  Clin Cancer Res       Date:  2018-12-05       Impact factor: 12.531

Review 2.  An epigenetic gateway to brain tumor cell identity.

Authors:  Stephen C Mack; Christopher G Hubert; Tyler E Miller; Michael D Taylor; Jeremy N Rich
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

3.  An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells.

Authors:  A Jakobs; S Uttarkar; C Schomburg; S Steinmann; A Coulibaly; P Schlenke; W E Berdel; C Müller-Tidow; T J Schmidt; K-H Klempnauer
Journal:  Leukemia       Date:  2016-02-08       Impact factor: 11.528

4.  Mapping regulatory elements.

Authors:  Yuexin Zhou; Wensheng Wei
Journal:  Nat Biotechnol       Date:  2016-02       Impact factor: 54.908

Review 5.  Lingering Questions about Enhancer RNA and Enhancer Transcription-Coupled Genomic Instability.

Authors:  Gerson Rothschild; Uttiya Basu
Journal:  Trends Genet       Date:  2017-01-10       Impact factor: 11.639

6.  IW-Scoring: an Integrative Weighted Scoring framework for annotating and prioritizing genetic variations in the noncoding genome.

Authors:  Jun Wang; Abu Z Dayem Ullah; Claude Chelala
Journal:  Nucleic Acids Res       Date:  2018-05-04       Impact factor: 16.971

7.  Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.

Authors:  Anica M Wandler; Benjamin J Huang; Jeffrey W Craig; Kathryn Hayes; Hannah Yan; Lauren K Meyer; Alessandro Scacchetti; Gabriela Monsalve; Monique Dail; Qing Li; Jasmine C Wong; Olga Weinberg; Robert P Hasserjian; Scott C Kogan; Philip Jonsson; Keith Yamamoto; Deepak Sampath; Joy Nakitandwe; James R Downing; Jinghui Zhang; Jon C Aster; Barry S Taylor; Kevin Shannon
Journal:  Leukemia       Date:  2020-02-17       Impact factor: 11.528

8.  HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.

Authors:  Yuqing Sun; Bo Zhou; Fengbiao Mao; Jing Xu; Hongzhi Miao; Zhenhua Zou; Le Tran Phuc Khoa; Younghoon Jang; Sheng Cai; Matthew Witkin; Richard Koche; Kai Ge; Gregory R Dressler; Ross L Levine; Scott A Armstrong; Yali Dou; Jay L Hess
Journal:  Cancer Cell       Date:  2018-09-27       Impact factor: 31.743

9.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

Authors:  Tinghu Zhang; Nicholas Kwiatkowski; Calla M Olson; Sarah E Dixon-Clarke; Brian J Abraham; Ann K Greifenberg; Scott B Ficarro; Jonathan M Elkins; Yanke Liang; Nancy M Hannett; Theresa Manz; Mingfeng Hao; Bartlomiej Bartkowiak; Arno L Greenleaf; Jarrod A Marto; Matthias Geyer; Alex N Bullock; Richard A Young; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2016-08-29       Impact factor: 15.040

Review 10.  Enhancer deregulation in cancer and other diseases.

Authors:  Hans-Martin Herz
Journal:  Bioessays       Date:  2016-08-29       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.